Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ..
In clinical neurology practice, there are few sensitive, specific and responsive serological biomarkers reflecting pathological processes affecting the peripheral nervous system. Instead, we rely on surrogate multimodality biomarkers for diagnosis and management. Correct use and interpretation of the available tests is essential to ensure that appropriate treatments are used and adjusted in a timely fashion. The incorrect application or interpretation of biomarkers can result in misdiagnosis and delays in appropriate treatment. Here, we discuss the uses and limitations of such biomarkers and discuss possible future developments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Practical neurology - (2022) vom: 18. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keh, Ryan Yann Shern [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CLINICAL NEUROLOGY |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1136/pn-2022-003438 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343711702 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343711702 | ||
| 003 | DE-627 | ||
| 005 | 20240217231948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/pn-2022-003438 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM343711702 | ||
| 035 | |a (NLM)35850979 | ||
| 035 | |a (PII)pn-2022-003438 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keh, Ryan Yann Shern |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a In clinical neurology practice, there are few sensitive, specific and responsive serological biomarkers reflecting pathological processes affecting the peripheral nervous system. Instead, we rely on surrogate multimodality biomarkers for diagnosis and management. Correct use and interpretation of the available tests is essential to ensure that appropriate treatments are used and adjusted in a timely fashion. The incorrect application or interpretation of biomarkers can result in misdiagnosis and delays in appropriate treatment. Here, we discuss the uses and limitations of such biomarkers and discuss possible future developments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CLINICAL NEUROLOGY | |
| 650 | 4 | |a NEUROPATHY | |
| 650 | 4 | |a NEUROPHYSIOLOGY | |
| 650 | 4 | |a NEURORADIOLOGY | |
| 700 | 1 | |a Shah, Sachit |e verfasserin |4 aut | |
| 700 | 1 | |a Lilleker, James B |e verfasserin |4 aut | |
| 700 | 1 | |a Lavin, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Morrow, Jasper |e verfasserin |4 aut | |
| 700 | 1 | |a Carr, Aisling S |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, Michael P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Practical neurology |d 2007 |g (2022) vom: 18. Juli |w (DE-627)NLM169632148 |x 1474-7766 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:18 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/pn-2022-003438 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 18 |c 07 | ||